Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates.
Related news for (ROIV)
- Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
- Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
- Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
- Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement